{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:31:18Z","timestamp":1764174678503,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.anl.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:37:42Z","timestamp":1561455462000},"page":"485-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"47","author":[{"given":"Shinsuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Toyoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Iikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takechiyo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2019.06.004_bib0005","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2019.06.004_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkmate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.anl.2019.06.004_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non\u2013small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1759-7714.12543","article-title":"Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy","volume":"9","author":"Ogawara","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.anl.2019.06.004_bib0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.oraloncology.2018.04.013","article-title":"Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy","volume":"81","author":"Daste","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jjco\/hyi058","article-title":"Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications","volume":"35","author":"Kodaira","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A randomized, open-label, phase III clinical trial of nivolumab vs. therapy of investigator\u2019s choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0050","first-page":"237","article-title":"Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells","volume":"19","author":"Sung","year":"2005","journal-title":"In Vivo"},{"key":"10.1016\/j.anl.2019.06.004_bib0055","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2019.06.004_bib0060","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2019.06.004_bib0065","first-page":"1","article-title":"Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy","author":"Sun","year":"2019","journal-title":"Head Neck"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814619302731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814619302731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:35:48Z","timestamp":1759952148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814619302731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0385814619302731"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2019.06.004","relation":{},"ISSN":["0385-8146"],"issn-type":[{"type":"print","value":"0385-8146"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}